Related Experiment Video

Updated: Jun 10, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Targeted therapy: an evolving world of lung cancer

Kwok-Chi Lam1, Tony S Mok

  • 1State Key Laboratory of Southern China, The Chinese University of Hong Kong, Sir YK Pau Cancer Center, Prince of Wales Hospital, Hong Kong, China.

Respirology (Carlton, Vic.)
|August 21, 2010
PubMed

Insights

Personalized medicine revolutionizes lung cancer treatment. Epidermal growth factor receptor (EGFR) targeted therapies offer superior outcomes for patients with specific mutations, marking a new era in oncology.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Lung cancer is a leading cause of mortality.
  • Advances in cancer genomics and targeted therapy are transforming treatment paradigms.
  • Epidermal growth factor receptor (EGFR) mutations are key drivers in non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To review the impact of molecular targeted therapy in advanced-stage NSCLC.
  • To highlight the efficacy of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated NSCLC.
  • To discuss the potential of anti-angiogenic therapies.

Main Methods:

  • Review of randomized clinical trials and scientific literature.
  • Analysis of treatment outcomes based on molecular biomarkers.
  • Exploration of therapeutic strategies targeting tumor vasculature.

Main Results:

  • EGFR TKIs (gefitinib, erlotinib) demonstrate superior efficacy compared to chemotherapy in EGFR-mutated NSCLC patients.
  • Targeting vascular endothelial growth factor (VEGF) is a promising strategy to enhance chemotherapy efficacy.
  • Lack of a practical biomarker for anti-angiogenic therapy efficacy remains a challenge.

Conclusions:

  • Personalized therapy based on molecular profiling is the future of lung cancer management.
  • EGFR-targeted therapies represent a significant advancement for a subset of NSCLC patients.
  • Further research into biomarkers for anti-angiogenic treatments is warranted.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...